



Minomic International Ltd Company Profile

Overview

Minomic International Ltd is an Australian immuno-oncology company that has developed an *in vitro diagnostic* test for the early detection of prostate cancer. The test, known as MiCheck® detects biomarkers present in the blood of patients. In clinical trials, MiCheck® has been shown to be more than twice as specific as the existing gold standard, prostate specific antigen (PSA) testing.

The company also has a clinical antibody program and has commenced a first-in-human trial with 12 cancer patients to develop diagnostic imaging and therapeutic applications of the MIL-38 antibody for prostate and other cancers. This uses the same technology as the diagnostic test and patient grade material has been produced for this study.

Both diagnostic and therapeutic applications of the technology are protected by Minomic's intellectual property estate.

Speaker Profile

Dr Brad Walsh, Chief Executive Officer



Dr Brad Walsh is Chief Executive Officer of Minomic International Ltd, a Sydney based immuno-oncology company. One of Dr. Walsh's most significant contributions is the development of diagnostics and therapeutics for solid tumours such as prostate and bladder. The technologies are based on the discovery of protein biomarkers unique to prostate cancer and the use antibodies to these markers for the diagnosis and treatment of these diseases.

Dr Walsh has 35 years' experience in the biotechnology business and has enjoyed a successful career commercializing IVD and proteomics products. He has been pivotal in raising \$25M in investment capital to progress Minomic's products.

continued...



In the early 2000's he founded the predecessor of Minomic International Ltd as a private company for which he raised over \$5M in equity investment and non-dilutive funding. In the mid-90's he was the inaugural General Manager of an Australian National Research Facility that was the world leader in the groundbreaking new field of proteomics.

Prior to this he led research groups in public institutions such as CSIRO, universities and hospitals. With his background both industry and government have eagerly sought his opinion as a thought leader and technologist. He holds the position of Adjunct Professor at Macquarie University. He has co-authored 76 peer reviewed papers and book chapters and six patents. He has co-supervised 7 PhD students and numerous honours students.

For more information, please visit: minomic.com